Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 35

1.

Trends in Human Papillomavirus-Associated Cancers - United States, 1999-2015.

Van Dyne EA, Henley SJ, Saraiya M, Thomas CC, Markowitz LE, Benard VB.

MMWR Morb Mortal Wkly Rep. 2018 Aug 24;67(33):918-924. doi: 10.15585/mmwr.mm6733a2.

2.

Plasma levels and diagnostic utility of macrophage-colony stimulating factor, matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 as tumor markers in cervical cancer patients.

Zajkowska M, Zbucka-Krętowska M, Sidorkiewicz I, Lubowicka E, Gacuta E, Szmitkowski M, Chrostek L, Ławicki S.

Tumour Biol. 2018 Jul;40(7):1010428318790363. doi: 10.1177/1010428318790363.

PMID:
30052166
3.

Results of Cervical Cancer Screening in the Rural Population of Lucknow West, India, through a Camp Approach.

Misra JS, Srivastava AN, Gupta HP.

Acta Cytol. 2018;62(4):273-278. doi: 10.1159/000489078. Epub 2018 Jun 13.

PMID:
29898440
4.

Clinical efficacy of p16/Ki-67 dual-stained cervical cytology in secondary prevention of cervical cancer.

Celewicz A, Celewicz M, Wężowska M, Chudecka-Głaz A, Menkiszak J, Urasińska E.

Pol J Pathol. 2018;69(1):42-47. doi: 10.5114/pjp.2018.75335.

5.

Evaluation of the LC-1000 Flow Cytometry Screening System for Cervical Cancer Screening in Routine Health Checkups.

Heo I, Kwak HJ, Nah EH, Cho S, Kim S, Cho HI.

Acta Cytol. 2018;62(4):279-287. doi: 10.1159/000489079. Epub 2018 May 29.

PMID:
29843120
6.

Individual- and county-level predictors of cervical cancer screening: a multi-level analysis.

Akinlotan MA, Weston C, Bolin JN.

Public Health. 2018 Jul;160:116-124. doi: 10.1016/j.puhe.2018.03.026. Epub 2018 May 26.

PMID:
29803186
7.

Comorbidity and cervical cancer survival of Indigenous and non-Indigenous Australian women: A semi-national registry-based cohort study (2003-2012).

Diaz A, Baade PD, Valery PC, Whop LJ, Moore SP, Cunningham J, Garvey G, Brotherton JML, O'Connell DL, Canfell K, Sarfati D, Roder D, Buckley E, Condon JR.

PLoS One. 2018 May 8;13(5):e0196764. doi: 10.1371/journal.pone.0196764. eCollection 2018.

8.

The Onclarity Human Papillomavirus Trial: Design, methods, and baseline results.

Stoler MH, Wright TC Jr, Parvu V, Vaughan L, Yanson K, Eckert K, Karchmer T, Kodsi S, Cooper CK.

Gynecol Oncol. 2018 Jun;149(3):498-505. doi: 10.1016/j.ygyno.2018.04.007. Epub 2018 Apr 19.

9.

Validation of a new HPV self-sampling device for cervical cancer screening: The Cervical and Self-Sample In Screening (CASSIS) study.

El-Zein M, Bouten S, Louvanto K, Gilbert L, Gotlieb W, Hemmings R, Behr MA, Franco EL; CASSIS Study Group.

Gynecol Oncol. 2018 Jun;149(3):491-497. doi: 10.1016/j.ygyno.2018.04.004. Epub 2018 Apr 17.

PMID:
29678360
10.

Exploring Effective Contextual Factors for Regular Cervical Cancer Screening in Iranian Women: A Qualitative Study

Refaei M, Dehghan Nayeri N, Khakbazan Z, Yazdkhasti M, Shayan A.

Asian Pac J Cancer Prev. 2018 Feb 26;19(2):533-539.

11.

'It has saved thousands of lives, so why change it?' Content analysis of objections to cervical screening programme changes in Australia.

Obermair HM, Dodd RH, Bonner C, Jansen J, McCaffery K.

BMJ Open. 2018 Feb 13;8(2):e019171. doi: 10.1136/bmjopen-2017-019171.

12.

Type-Specific Human Papillomavirus Prevalence in Iranian Women with Normal Cervical Cytology: The Impact of Current HPV Vaccines.

Hamkar R, Shoja Z, Ghavami N, Heydari N, Farahmand M, Jalilvand S.

Intervirology. 2017;60(4):125-130. doi: 10.1159/000485898. Epub 2018 Jan 25.

13.

Descriptive Epidemiology of Cancers in Togo from 2009 to 2016

Darre T, Kpatcha TM, Bagny A, Maneh N, Gnandi-Piou F, Tchangai B, Daré S, Adani-Ifé S, Walla A, Amégbor K, Napo-Koura G.

Asian Pac J Cancer Prev. 2017 Dec 29;18(12):3407-3411.

14.

Limited Understanding of Pap Smear Testing among Women, a Barrier to Cervical Cancer Screening in the United Arab Emirates

AL-Hammadi FA, Al-Tahri F, Al-Ali A, Nair SC, Abdulrahman M.

Asian Pac J Cancer Prev. 2017 Dec 29;18(12):3379-3387.

15.

Human Papilloma Virus Genotype Distribution in Cervical lesions in Zanjan, Iran

Ahmadi S, Goudarzi H, Jalilvand A, Esmaeilzadeh A.

Asian Pac J Cancer Prev. 2017 Dec 29;18(12):3373-3377.

17.

The next Sub Saharan African epidemic? A case study of the determinants of cervical cancer knowledge and screening in Kenya.

Kangmennaang J, Onyango EO, Luginaah I, Elliott SJ.

Soc Sci Med. 2018 Jan;197:203-212. doi: 10.1016/j.socscimed.2017.12.013. Epub 2017 Dec 14.

PMID:
29253722
18.

Temporal trend in socioeconomic inequalities in the uptake of cancer screening programmes in France between 2005 and 2010: results from the Cancer Barometer surveys.

Kelly DM, Estaquio C, Léon C, Arwidson P, Nabi H.

BMJ Open. 2017 Dec 14;7(12):e016941. doi: 10.1136/bmjopen-2017-016941.

19.

Self-sampling for human papillomavirus testing among rural young women of KwaZulu-Natal, South Africa.

Mbatha JN, Galappaththi-Arachchige HN, Mtshali A, Taylor M, Ndhlovu PD, Kjetland EF, Baay MFD, Mkhize-Kwitshana ZL.

BMC Res Notes. 2017 Dec 6;10(1):702. doi: 10.1186/s13104-017-3045-3. Erratum in: BMC Res Notes. 2018 Feb 26;11(1):153.

20.

Prevalence of human papillomavirus genotypes and precancerous cervical lesions in a screening population in the Republic of Korea, 2014-2016.

Ouh YT, Min KJ, Cho HW, Ki M, Oh JK, Shin SY, Hong JH, Lee JK.

J Gynecol Oncol. 2018 Jan;29(1):e14. doi: 10.3802/jgo.2018.29.e14.

Supplemental Content

Loading ...
Support Center